Defense Logistics Agency Awards Fujifilm a Five-Year Contract to Provide Endoscopic Equipment, Technology and Training

All U.S. Federal Government medical treatment facilities will have access to Fujifilm’s advanced endoscopic suite of innovative solutions

Lexington, Mass., April 13, 2022 — FUJIFILM Healthcare Americas Corporation, a leading provider of endoscopic and endosurgical solutions, has been awarded a five-year, multi-million-dollar contract by the U.S. Defense Logistics Agency Troop Support, to supply Fujifilm’s innovative endoscopy solutions and equipment training to all hospitals and ambulatory surgery centers operated by the U.S. military as well as the Veteran’s Health Administration, National Institutes of Health, Indian Health Service, and more.

“We are particularly honored to serve those who represent their nation so proudly in military and public service,” said Taisuke Fujita, vice president, Endoscopy, FUJIFILM Healthcare Americas Corporation. “We are determined to deliver the most advanced technology to the medical teams at each of the institutions covered by this monumental agreement.”

The awarded contract reflects Fujifilm’s entire portfolio of endoscopic solutions, including their 700 Series standard, slim, treatment, and zoom colonoscopes, which enable gastroenterologists to adapt their technology based on their patient’s anatomy and clinical need, as well as the ELUXEO Endoscopic Imaging, which delivers three visualization modes: Ultra-HD White Light Endoscopy, Blue Light Imaging (BLI) and Linked Color Imaging (LCI) to support improved detection and visualization during exams.

Fujita made special note of the importance of advanced endoscopic equipment in detecting and addressing colorectal cancer (CRC): “Colorectal cancer is the second leading cause of cancer death in the United States, the third most common diagnosed cancer among indigenous Americans, and the fourth most common diagnosed cancer among veterans. With our endoscopy portfolio, we hope to transform the speed and accuracy with which CRC is identified, addressed and managed at all federally-managed healthcare sites.”

“This contract speaks to the confidence and level of trust that federal agencies have put in Fujifilm’s high quality imaging technology,” said Lou Cavallaro, National Director, Government Business, FUJIFILM Healthcare Americas Corporation. “Today’s announcement follows other significant 2021 multi-year federal awards, most notably a 4-Year Standardization Award to provide Fujifilm’s innovative Persona C mobile fluoroscopy system for the U.S. Army and a 10-Year Standardization Award to provide Fujifilm’s innovative Digital X-ray systems for the U.S. Naval Fleet.”

To learn more about Fujifilm’s endoscopy portfolio, visit

About Fujifilm

FUJIFILM Healthcare Americas Corporation is a leading innovator in diagnostic and enterprise imaging solutions designed to meet the evolving needs of healthcare across prevention, diagnosis, and treatment. Fujifilm’s medical imaging portfolio includes solutions for digital radiography, mammography, computed tomography, magnetic resonance imaging, ultrasound, endoscopy, and endosurgery. The Synapse® Enterprise Imaging portfolio provides healthcare professionals with the imaging and data access needed to deliver a complete patient record. REiLI®, Fujifilm’s artificial intelligence initiative, combines Fujifilm’s rich image -processing heritage with cutting-edge AI innovations to inspire a new tier of clinical confidence. The In-Vitro Diagnostic portfolio provides the golden standard of molecular based immunoassay technology for liver surveillance, cutting edge clinical diagnostic chemicals for leading laboratories across the country and diagnostic chemicals for OEM white labeling products. The company is headquartered in Lexington, Massachusetts. For more information please visit

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit:


Danielle Brown 

Previous Press Release United Digestive Selects Fujifilm Medical Systems as Exclusive Vendor of Choice to Offer Enhanced Endoscopic Services to its Patients Next Press Release Fujifilm Awarded Pacific Air Force/Navy Order from the U.S. Department of Defense and Defense Logistics Agency for Synapse PACS